| Document |
Document Title |
|
WO/2024/059629A1 |
The present disclosure relates to a combination therapy comprising an immune checkpoint inhibitor, a nanoparticle formulated plasmid comprising an IL-12 coding nucleic acid, and, optionally, at least one adjunctive chemotherapeutic drug,...
|
|
WO/2024/057094A2 |
Human interleukin-2 (IL-2) muteins or variants thereof are provided. Also provided are pharmaceutical compositions that include such IL-2 muteins.
|
|
WO/2024/056560A1 |
The present invention relates to a recombinant expression vector encoding an inducible cell death switch, a pH-stable fluorophore and a pH-sensitive fluorophore. Moreover, the invention relates to cells comprising said recombinant expres...
|
|
WO/2024/057793A1 |
Provided is a peptide which comprises no more than 25 amino acids and has an amino acid sequence of (i) or (ii). An amino acid sequence comprises the same citrulline as three or more citrullines in a partial sequence of SEQ ID NO: 1., wi...
|
|
WO/2024/059667A2 |
The disclosure is directed in part to variant capsid polypeptides that can be used to deliver pay loads.
|
|
WO/2024/059550A1 |
The present disclosure provides compositions comprising nucleic acid double-stranded splint adaptors, including kits, and methods that employ the double-stranded splint adaptors. The double-stranded splint adaptors (200) can be used in a...
|
|
WO/2024/055291A1 |
The present invention relates to a sirtuin mutant, a method for high-throughput screening of a sirtuin mutant, and use. The screening method for a sirtuin mutant comprises the following steps: constructing a sirtuin mutant library using ...
|
|
WO/2024/056106A1 |
Provided are a vesicular stomatitis virus vector, which comprises sgVSV (△L/L) and sgVSV (△G/G), which can load and express an exogenous gene, is lower in toxicity relative to a wild type strain, has a smaller likelihood of recombina...
|
|
WO/2024/057338A1 |
The present disclosure provides a method for expressing miR-449a in a neuronal cell by administering a viral vector comprising a nucleotide sequence containing a miRNA-449a sequence. The present disclosure also provides a method for trea...
|
|
WO/2024/055995A1 |
Provided are an anti-VEGFA fusion protein, and a preparation method therefor and the use thereof. The anti-VEGFA fusion protein has a high affinity with VEGFA, can effectively block the binding of VEGFA to receptor VEGFR, block a VEGFA s...
|
|
WO/2024/059681A2 |
Disclosed herein are compositions and method for identifying genes that improve or enhance pathogen resistance. Compositions comprising effector polypeptides encoded by the polynucleotides disclosed herein are useful in identifying genes...
|
|
WO/2024/055988A1 |
Provided are an isolated polypeptide consisting of a mutant B domain of Protein A, an unnatural immunoglobulin binding protein containing the mutant B domain, a conjugate containing the mutant B domain or the unnatural immunoglobulin bin...
|
|
WO/2024/057339A1 |
The present disclosure provides methods for treating a cognitive impairment due to Itch dysregulation in a patient by administering a viral vector comprising a polynucleotide sequence encoding an Itch mutant to the patient. The Itch muta...
|
|
WO/2024/059543A2 |
The invention provides novel recombinant DNA, compositions, and methods for selectively regulating the expression of a transcribable polynucleotide or recombinant protein in pollen of a transgenic plant. The invention also provides trans...
|
|
WO/2024/056098A1 |
Provided are an NK cell adapter molecule targeting an NKG2D ligand and an NKp46 and the use thereof. The cell adapter molecule at least comprises: a first binding domain comprising an NKG2D extracellular domain that can specifically bind...
|
|
WO/2024/056664A1 |
The invention relates to a process for programing a single cell or a group of cells to become malignant, comprising the following steps a) providing cell(s) with the following features: o expressing a dedifferentiation factor, and o comp...
|
|
WO/2024/059699A2 |
Described herein are methods and compositions for generating single sex offspring using trans-splicing approach. In particular, methods and compositions are provided to generate single sex and genetically modified offspring. These techni...
|
|
WO/2024/055735A1 |
Provided are a genetically engineered bacterium with high yield of gibberellin acid GA 3, a construction method, and use. By means of enhanced expression of a gene expressing cytochrome P450 reductase CPR and a gene encoding vitreoscilla...
|
|
WO/2024/056643A1 |
The present invention relates to nucleic acid constructs comprising a first polynucleotide encoding a signal peptide, e.g., from a fungal glycosidase, and a second polynucleotide encoding an alpha-lactalbumin (ALAB) polypeptide; expressi...
|
|
WO/2024/059864A2 |
The present disclosure provides novel large serine recombinases and their cognate attachment sites in the human genome. Methods for using these large serine recombinases and attachment sites are also provided herein.
|
|
WO/2024/059851A1 |
Some aspects of this invention provide engineered microbes for oil production. Methods for microbe engineering and for use of engineered microbes are also provided herein. In some embodiments, microbes provided are engineered to produce ...
|
|
WO/2024/059542A2 |
A system to perform reversible transvenous electroporation includes an electroporation generator and a controller operably coupled to the electroporation generator. The controller is configured to instruct the electroporation generator t...
|
|
WO/2024/055664A1 |
The present invention relates to the technical field of biology, and particularly, to an optimized guide RNA, a CRISPR/AcC2C9 gene editing system, and a gene editing method. The guide RNA comprises an RNA framework and a gene targeting s...
|
|
WO/2024/059632A1 |
This disclosure provides expression systems comprising secretion signals that promote production and/or secretion of proteins of interest, as well as one or more polynucleotides encoding chaperone proteins (e.g., CRT and/or PDIA3) which,...
|
|
WO/2024/051871A2 |
Disclosed is a method and application for constructing a WSB2 gene knockout monoclonal cell strain and a use thereof. The method comprises utilizing a CRISPR/Cas9 system to prepare a WSB2 gene knockout monoclonal cell strain; first, two ...
|
|
WO/2024/052919A1 |
The present invention provides polynucleotide sequences derived from Helichrysum umbraculigerum and encoding a protein or a plurality thereof belonging to the polyketide synthase (PKS) family. Further provided are an artificial nucleic a...
|
|
WO/2024/055013A1 |
The present disclosure provides systems and methods for transposing a cargo nucleotide sequence to a target nucleic acid site. These systems and methods may comprise a first double-stranded nucleic acid comprising the cargo nucleotide se...
|
|
WO/2024/054424A1 |
The present disclosure provides novel PD1 Ab-IL-2 immunocytokines and VitoKine compositions that aim to target a potency-attenuated or a bio-activable IL-2 directly to tumor-infiltrating lymphocytes to reduce systemic mechanism-based tox...
|
|
WO/2024/053630A1 |
The present disclosure provides a new carrier peptide fragment having cell membrane permeability. The disclosed carrier peptide fragment comprises the following amino acid sequence: RKLAVYWSTYKRSR (SEQ ID NO: 1).
|
|
WO/2024/051211A1 |
The present invention provides a pharmaceutical composition for preventing hepatitis B virus infection and use thereof. The pharmaceutical composition comprises i) hepatitis B virus surface antigen, a fragment thereof with antigenic acti...
|
|
WO/2024/051077A1 |
The present invention relates to a transgenic soybean event CAL16 and a detection method therefor. The transgenic soybean event CAL16 refers to a DNA molecule obtained when an exogenous gene (i.e., T-DNA) is inserted between a 3' end rep...
|
|
WO/2024/051616A1 |
Provided is a polypeptide, which has: (I) an amino acid sequence set forth in any one of SEQ ID No. 1, SEQ ID No. 4, and SEQ ID No. 5; or (II), an amino acid sequence obtained by substitution, deletion, or addition of one or more amino a...
|
|
WO/2024/052430A1 |
The invention relates to a Pseudomonas sp. strain for use in the production of a recombinant protein characterised in that said strain comprises a nucleotide sequence encoding a phi15 RNA polymerase.The invention further relates to a pla...
|
|
WO/2024/052681A1 |
The present disclosure relates to compositions for use in the treatment of a class of Rett syndrome mutations, namely C-terminal deletions, comprising a base editor to alter a stop codon in a mutant MECP2 gene. This alteration does not r...
|
|
WO/2024/054047A1 |
A self-circularization RNA structure of the present invention is expressed in a DNA vector and, at the same time, can form circRNA by circularization through self-targeting and splicing reactions, wherein the circRNA may be composed of o...
|
|
WO/2024/054850A1 |
The present disclosure relates to RNA sequences, compositions, and methods of use to prevent viral replication, prevent RNA polymerase activity, activate innate immune responses, or combinations thereof.
|
|
WO/2024/052918A1 |
The present invention provides an isolated DNA molecule including at least a first nucleic acid sequence encoding a first protein and at least a second nucleic acid sequence encoding a second protein, wherein the first protein and the se...
|
|
WO/2024/052934A2 |
The present invention provides modified Cry1Ac protein having enhanced toxicity towards resistant pink bollworm (PBW) species. Insertion of said specific, tightly binding gut peptides in Cry1Ac at one or more identified sites increases t...
|
|
WO/2024/054201A1 |
Provided herein are methods and compositions for identifying α-synuclein aggregation inhibitors. Also provided are methods of use of the α-synuclein aggregation inhibitors; the methods include methods of inhibition the formation of Lew...
|
|
WO/2024/054979A1 |
The present disclosure is directed to a genetic construct for performing loopable translation, a kit comprising the genetic construct, and a method of producing biomaterials comprising a highly repetitive protein by use of the genetic co...
|
|
WO/2024/052318A1 |
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM) targeting B-cell maturation antigen (BCMA) induces high overall response rates. However, relapse occurs frequently and novel strategies for CAR-T cells targeting MM...
|
|
WO/2024/051057A1 |
Disclosed is a multi-target chimeric antigen receptor comprising CD38 targeting. The CAR-T cells prepared by the present invention can be effectively expanded in vitro, have a very strong killing effect on multiple myeloma cells expressi...
|
|
WO/2024/053933A1 |
Unlike DNA, mRNA has the advantage of enabling transient expression of a desired protein directly in the cytoplasm without having to enter the nucleus, and thus, attempts to use mRNA vaccines are actively underway. However, mRNA has lowe...
|
|
WO/2024/053721A1 |
[Problem] To provide a therapeutic for spinal cord injury, especially severe spinal cord injury, from the acute phase to the subacute phase, the conventional treatment of which has been difficult. [Solution] A therapeutic for spinal cord...
|
|
WO/2024/051096A1 |
The present invention belongs to the technical field of molecular biology. Provided are an anti-CD40 nanobody, and a preparation method therefor and the use thereof. The provided anti-CD40 nanobody has three unique complementarity determ...
|
|
WO/2024/051751A1 |
Disclosed herein are anti-CD123 nanobodies, a chimeric antigen receptor, and use thereof. The nanobodies are VHH01 and VHH02. The nanobodies VHH01 and VHH02 both have good affinity and specificity for CD123. A chimeric antigen receptor a...
|
|
WO/2024/051855A1 |
A nucleic acid construct and use thereof in an IVTT system. Specifically provided is a nucleic acid construct. The nucleic acid construct has a structure of formula (I): Z1-Z2-Z3-Z4-Z5 (I). In the formula, Z1-Z5 are elements for constitu...
|
|
WO/2024/053642A1 |
According to one aspect of the present invention, this method for detecting Fusobacterium nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific...
|
|
WO/2023/077029A9 |
The invention provides single-cell analysis using combined DNA sequencing of genomic DNA, which is performed to determine whether a segment of foreign DNA has been integrated. Individual cells are encapsulated with reagents, including pr...
|
|
WO/2024/055002A1 |
Provided are a fusion protein comprising a mutated kinetochore protein and dCas9. The fusion protein is used in conjunction with guide RNAs target the fusion protein to a location of kinetochore assembly on a centromere such that the fus...
|
